Two teams from leading institutions go head-to-head to debate the latest datasets and advances in multiple myeloma.
EP. 1: Team Introductions: The Memorial Sloan Kettering “Yankees” vs The Dana-Farber “Red Sox”
Steven Frommeyer introduces the two teams of competing physicians participating in Cancer Network® Face-off.
EP. 2: Relapsed/Refractory Multiple Myeloma and the INSURE Study
Clifton Mo, MD, presents data from the INSURE study, a pooled analysis evaluating patients with relapsed/refractory multiple myeloma treated with Ixazomib-Lenalidomide-Dexamethasone (IRd).
EP. 3: Cross Q&A: Ixazomib in Multiple Myeloma
Dr Clifton Mo fields questions from the Memorial Sloan Kettering team about his presentation on IRd in relapsed/refractory multiple myeloma.
EP. 4: Treatment of Late Relapse Multiple Myeloma with Belantamab Mafodotin
Shonali Midha, MD, highlights data from the DREAMM-5 study during her presentation on the use of belantamab mafodotin for late relapse multiple myeloma.
EP. 5: Data on Real-World Use of Belantamab Mafodotin in R/R MM
Dr Shonali Midha continues her analysis of belantamab mafodotin with a look at data on real-world use in R/R MM since its FDA approval in August 2020.
EP. 6: Cross Q&A: Belantamab for Multiple Myeloma Treatment
Malin Hultcrantz, MD, PhD, questions Shonali Midha, MD, about the data she presented on belantamab mafodotin in patients with relapsed/refractory multiple myeloma.
EP. 7: Recap: MSKCC and DFCI Debate Current Treatment Strategies in Multiple Myeloma
Experts from leading institutions debate the latest advances in multiple myeloma.
2 Commerce Drive Cranbury, NJ 08512